What FibroGen China does

Kyntra Bio (formerly FibroGen, rebranded January 2026) is a clinical-stage biopharmaceutical company headquartered in San Francisco that develops therapeutics for oncology and rare-disease anemia. The company's pipeline is anchored by two programs: roxadustat, an oral small-molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in China, Europe, Japan and numerous other markets for anemia in chronic kidney disease and in Phase 3 development for anemia in lower-risk myelodysplastic syndromes (LR-MDS); and FG-3246, a potential first-in-class fully human antibody-drug conjugate targeting CD46, comprising the anti-CD46 antibody YS-5 linked to MMAE, currently in Phase 2 for metastatic castration-resistant prostate cancer (mCRPC). A companion CD46-targeted PET imaging agent, FG-3180, is being co-developed to identify CD46-positive lesions and support predictive patient selection for FG-3246 therapy.

The business model is pre-commercial: Kyntra Bio has no approved products in its current pipeline and generates no product revenue. Commercialization is executed through partners — Astellas Pharma holds roxadustat rights across Japan, Europe, the Middle East, Russia/CIS, Turkey, South Africa and select other territories under a partnership established in 2004, while FG-3246 was in-licensed from Fortis Therapeutics in May 2023. Kyntra Bio retains roxadustat rights in the U.S., Canada, Mexico and all non-partnered markets. In November 2025, the company divested its China operations (FibroGen China) to AstraZeneca for approximately $220 million, a transaction that funded a strategic refocus and extended cash runway into 2028. The company trades on Nasdaq as KYNB following a 1-for-25 reverse stock split executed in June 2025.

Kyntra Bio serves patient populations with significant unmet medical need: approximately 60,000 U.S. adults with LR-MDS (of whom roughly 85% develop anemia, and fewer than 50% achieve transfusion independence on current therapy), and approximately 65,000 U.S. drug-treatable mCRPC cases annually with 5-year survival near 30%. The company employs 101-250 staff, leans on investigator-sponsored and academic collaborations (including with UCSF), and conducts its go-to-market through medical/scientific conferences, ClinicalTrials.gov disclosures, investor relations, and corporate communications rather than direct sales infrastructure.

Name

FibroGen China

Legal name

Kyntra Bio, Inc.

Website

https://fibrogen.com

Company type

Public

Founded year

1993

Operating status

Operating

Headcount range

101–250 employees

Short description

Kyntra Bio (formerly FibroGen China) is a clinical-stage biopharmaceutical company developing roxadustat (oral HIF-PH inhibitor) for LR-MDS anemia and FG-3246, a CD46-targeted antibody-drug conjugate for metastatic castration-resistant prostate cancer.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Nephrology & Urology Pharmaceuticals (HLAIAAAM)

akta.pro secondary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Oncology therapeutics
• Anemia treatment
• Antibody-drug conjugate
• HIF-PH inhibitor
• Biopharmaceutical development

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Potential Commercialization: Pre-revenue biotech company. In Q3 2025, FibroGen sold FibroGen China to AstraZeneca for approximately $220 million. The company is developing roxadustat (approved in China, Europe, Japan for CKD anemia) and FG-3246 (Phase 2 for mCRPC) with no approved products yet in its current pipeline.

Go-to-market motion1 record

Marketing channels4 records

Core offering

FibroGen China operated as the China-based pharmaceutical subsidiary of FibroGen, focused on developing and commercializing roxadustat (an oral HIF-PH inhibitor for chronic kidney disease anemia) in the Chinese market. Following the Q3 2025 sale to AstraZeneca for ~$220 million, FibroGen China is no longer part of the parent (now rebranded as Kyntra Bio), which continues to advance the FG-3246 CD46-targeted ADC and roxadustat pipeline for oncology and rare disease indications.

Product overview

Kyntra Bio (formerly FibroGen) is a biopharmaceutical company pioneering oncology and rare disease therapies. The company's product portfolio centers on two key programs: Roxadustat, an oral HIF-PH inhibitor approved globally for anemia in chronic kidney disease and in Phase 3 development for LR-MDS; and the FG-3246/FG-3180 program featuring a CD46-targeted ADC (FG-3246) for mCRPC paired with a companion PET imaging agent (FG-3180) for patient selection. The company operates through strategic partnerships with Astellas Pharma (for roxadustat commercialization in Europe, Japan, and other territories) and Fortis Therapeutics (for FG-3246).

Differentiator

Problem solved

Functional benefit

Products and services

• Roxadustat An oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that promotes coordinated erythropoiesis by increasing endogenous erythropoietin, improving iron availability, and reducing hepcidin levels. Approved in China, Europe, Japan and numerous other countries for anemia in chronic kidney disease patients. Currently in Phase 3 development for lower-risk myelodysplastic syndromes (LR-MDS) anemia.
• FG-3246 A potential first-in-class, fully human antibody-drug conjugate (ADC) targeting CD46, comprised of anti-CD46 antibody YS-5 linked to monomethyl auristatin E (MMAE). Currently in Phase 2 development for metastatic castration-resistant prostate cancer (mCRPC) with potential for additional trials targeting other CD46-expressing cancers.
• FG-3180 A CD46-targeted PET imaging agent that uses the same antibody backbone as FG-3246. Being evaluated as an exploratory sub-study to detect CD46-positive lesions and support predictive patient selection for FG-3246 therapy.

Quantifiable outcome

• Approximately 60,000 adults diagnosed with LR-MDS in the U.S.
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• Fortis TherapeuticscoreStrategic or Co-development PartnerIn May 2023, Kyntra Bio entered into an exclusive license with Fortis Therapeutics for FOR46 (FG-3246), a potential first-in-class antibody-drug conjugate targeting CD46 for metastatic castration-resistant prostate cancer. Kyntra Bio initiated Phase 2 trial for FG-3246 in mCRPC with potential for additional trials targeting other CD46-expressing cancers. Also studying FG-3180, a PET-based biomarker to assess correlation between CD46 expression and FG-3246 response.
• Astellas PharmacoreStrategic or Co-development PartnerLongstanding strategic partnership established in 2004 focused on development and commercialization of roxadustat for anemia associated with chronic kidney disease. Collaboration grants Astellas rights to develop and market roxadustat in Japan, Europe, Middle East, Russia, Commonwealth of Independent States, Turkey, South Africa, and select other territories. Roxadustat is approved in multiple regions under this partnership. Kyntra Bio retains rights in U.S., Canada, Mexico, and all markets not held by Astellas (excluding China and South Korea).
• UCSF (University of California, San Francisco)supportingStrategic or Co-development PartnerClinical trials collaboration. Phase 1b/2 Study of FG-3246 (FOR46) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer conducted in partnership with UCSF. Kyntra Bio maintains active clinical trial programs with academic research institutions.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Pfizer: Co-markets enzalutamide with Astellas and has a broad oncology pipeline including ADCs and prostate cancer therapies, overlapping with Kyntra Bio's target indications.
• AstraZeneca: Acquired FibroGen China for ~$220M and has a major oncology and rare-disease franchise, including ADC platforms (Enhertu) that compete conceptually with FG-3246.
• Daiichi Sankyo: Global leader in ADC technology (Enhertu, Datroway), representing the standard against which next-generation ADCs like FG-3246 are benchmarked in oncology development.
• Bristol Myers Squibb: Major oncology player with ADCs and mCRPC therapies (e.g., OPDIVO combinations), and a CDK/mDS-adjacent hematology franchise overlapping with Kyntra Bio's LR-MDS anemia opportunity.
• Johnson & Johnson (Janssen): Develops apalutamide (Erleada) for mCRPC and operates a deep oncology and hematology portfolio, making it a benchmark incumbent in the prostate cancer space Kyntra Bio is pursuing.

Direct peers

• Akebia Therapeutics: Develops vadadustat, another oral HIF-PH inhibitor for anemia in chronic kidney disease — a direct competitor to roxadustat in the same mechanism and indications.
• Bayer: Markets darolutamide (Nubeqa) for mCRPC, a direct competitor to FG-3246, and is one of the established players in the prostate cancer treatment landscape Kyntra Bio targets.
• Astellas Pharma: Strategic partner on roxadustat and developer of enzalutamide (Xtandi), one of the leading therapies for metastatic castration-resistant prostate cancer — directly competing with FG-3246 in mCRPC.

Emerging players

• MacroGenics: Clinical-stage oncology company developing antibody-based therapeutics including ADCs, with comparable technology and pre-commercial profile to Kyntra Bio's FG-3246 program.
• Mereo BioPharma: Clinical-stage biopharma focused on rare disease and oncology, with a similar pre-commercial, partnership-driven model and a comparable mid-stage pipeline posture.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/FibroGenInc
• LinkedInlinkedin.com/company/fibrogen

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FibroGen China